New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are already underway in Florida, California, and Texas as the collaboration seeks to expand access to easily administered testing for the general public. The initiative is positioned to support case finding earlier in the disease course by making testing available outside traditional specialty clinics.

Under Life Line Screening’s mobile delivery model, testing is provided in local venues such as community centers, churches, and senior centers. Results can be shared with primary care physicians to help facilitate early intervention and proactive lifestyle management for adults. LLS operates in 48 states and hosts more than 15,000 community events annually, providing a scalable infrastructure that reaches major metropolitan areas and underserved rural regions.

Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

The partners highlight the scale of the need: an estimated 7 million Americans are living with Alzheimer’s disease today, with another 6–7 million experiencing symptoms of mild cognitive impairment. Lucent Diagnostics, created in 2023, focuses on tools that aid earlier detection of cognitive disease and is powered by ultra‑sensitive Simoa technology. By integrating these blood‑based biomarker capabilities into community screening, the program is intended to broaden access to information that can be used by physicians in routine care.

“Too many chronic conditions go undetected until they become life-altering events. By partnering with Lucent Diagnostics, we're able to continue to expand our mission of uncovering asymptomatic risks earlier and more equitably. This partnership has the potential to impact numerous lives by supporting more informed treatment pathways, and it’s something we’re excited to bring to communities across the country,” said Jim Waters, Chief Operating Officer at Life Line Screening.

“Scientific rigor shouldn’t stop at the laboratory door. Through LLS, Lucent Diagnostics is bringing validated, high-quality science into community testing networks, helping ensure that everyone has access to information for use by their physician and not only in a research setting. This is a critical step toward earlier, more reliable detection of Alzheimer’s Disease,” said Zachary Fernandes, Quanterix General Manager for Lucent Diagnostics.

Related Links
Lucent Diagnostics
Life Life Screening